The Body Pharm Retatrutide 32mg pen is a pre-filled research-grade injector delivering a complete 2mgβ4mgβ6mgβ8mg weekly titration protocol in a single device.
Retatrutide remains investigational, with Eli Lilly's May 2026 Phase 3 data showing up to 28.3% weight loss in high-dose obesity cohorts [9]. As a triple GLP-1/GIP/glucagon receptor agonist, it produces larger weight-loss figures in Phase 3 trials than dual-agonist tirzepatide or single-agonist semaglutide.
For research use only. Not for human consumption.
Key Takeaways
- The Body Pharm 32mg pen suits 8β12 week protocols; the 64mg variant targets longer studies.
- Retatrutide is a triple-agonist peptide (GLP-1 + GIP + glucagon), producing larger weight-loss figures in Phase 3 trials than dual-agonist tirzepatide or single-agonist semaglutide.
- No independent certificate of analysis (COA) exists for any Body Pharm retatrutide SKU as of May 2026.
- Retatrutide is not SAHPRA-registered and sits outside the medicines schedule; procurement requires Section 21 documentation under the Medicines and Related Substances Act 101 of 1965.
- The prefilled pen format removes the reconstitution step required by lyophilised vial alternatives, offering fixed-step dialling and reduced inter-operator variance.
What Is the Body Pharm Retatrutide 32mg Pen?
The Body Pharm Retatrutide 32mg pen is a pre-filled research-grade injector containing 32mg of retatrutide peptide, manufactured by Body Pharm, with a labelled 2mgβ4mgβ6mgβ8mg weekly titration schedule. It is supplied strictly as a research chemical, not for human consumption.
Retatrutide is a triple-agonist peptide that simultaneously activates the GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors β a mechanism originated by Eli Lilly and still classified as investigational as of 2026 [12]. Phase 2 obesity data published in the New England Journal of Medicine in 2023 reported up to 24.2% body-weight reduction over 48 weeks at the highest dose, and May 2026 Phase 3 read-outs extended that figure to 28.3% in high-dose cohorts [9]. That three-receptor activation separates retatrutide from single-receptor GLP-1 agents like semaglutide and dual-receptor GLP-1/GIP compounds like tirzepatide.
Regulatory Status in South Africa
Retatrutide is not registered with SAHPRA (South African Health Products Regulatory Authority) as of mid-2026, and no SAHPRA circular naming retatrutide has been published in the 2024β2026 window reviewed [unverified]. Under the Medicines and Related Substances Act 101 of 1965, unregistered investigational compounds sit outside routine scheduling and are handled case-by-case, typically via Section 21 for human clinical access. The Body Pharm 32mg pen is a grey-market research item, and procurement should be documented as such.
For the head-to-head dosing analysis, see the Body Pharm Retatrutide 64mg pen breakdown, or step up to the broader retatrutide research overview.
Triple-Agonist Mechanism: Why It Differs from GLP-1 Alone
Retatrutide binds and activates three incretin and metabolic receptors simultaneously: GLP-1, GIP, and glucagon. Semaglutide activates one receptor (GLP-1 only) and tirzepatide activates two (GLP-1 + GIP) [7][8]. That third arm β glucagon receptor agonism β is what separates retatrutide pharmacologically from every GLP-1 product currently on the South African research market.
GLP-1 receptor activation suppresses appetite via hypothalamic signalling and slows gastric emptying, which is the mechanism semaglutide exploits as a GLP-1-only agent [8]. GIP receptor activation potentiates glucose-dependent insulin secretion and modulates adipose tissue lipid handling; pairing GIP with GLP-1 gives tirzepatide its dual-agonist profile and the larger weight-loss delta over semaglutide reported in head-to-head trials [8].
What the Glucagon Arm Adds
Glucagon receptor agonism increases hepatic glucose output and raises resting energy expenditure. Balanced against GLP-1-driven appetite suppression and GIP-driven insulin response, it produces a net catabolic effect [8]. Retatrutide is the first clinical-stage molecule to combine all three. The NEJM 2023 Phase 2 obesity trial reported up to 24.2% body-weight reduction over 48 weeks at the highest dose, with May 2026 Phase 3 read-outs extending that to 28.3% in high-dose cohorts [7].
The receptor hierarchy is straightforward for researchers comparing compounds before procurement: semaglutide is single-receptor, tirzepatide is dual-receptor, retatrutide is triple-receptor. The Phase 2 and Phase 3 efficacy figures track that hierarchy in the same direction [7][8]. The retatrutide research overview covers the receptor pharmacology in more depth, and the Body Pharm Retatrutide 64mg pen page applies that same framework to the higher-strength SKU.
32mg Pen vs 64mg Pen: Which Format Suits Your Research?
The 32mg pen suits short, single-titration protocols of roughly 8β12 weeks because it delivers approximately four 8mg doses, covering the titration ramp plus one month of maintenance. The 64mg pen targets extended studies running 16 weeks or longer, where fewer device changeovers also reduce cold-chain breaks and re-equilibration cycles.
At the 8mg weekly marker, the 32mg pen delivers approximately four doses and the 64mg pen up to eight doses [unverified]. Neither figure has been corroborated by independent dose-accuracy testing, and no third-party COA for either Body Pharm SKU has been published as of 2026 [unverified].
Side-by-Side Specification Table
| Attribute | Body Pharm Retatrutide 32mg Pen | Body Pharm Retatrutide 64mg Pen |
|---|---|---|
| Total peptide content (label) | 32mg | 64mg (some listings also reference "164mg Retatrutide dihydrate" β see note) |
| Doses at 8mg weekly | ~4 [unverified] | up to 8 [unverified] |
| Current ZAR price | See buy box above | See product page |
| Titration coverage | Full 2β4β6β8mg ramp | Full ramp plus extended maintenance |
| Suitable protocol length | 8β12 weeks | 16+ weeks |
| Independent COA available | None located [unverified] | None located [unverified] |
| Shelf life / in-use stability | Not published by manufacturer [unverified] | Not published by manufacturer [unverified] |
| Reconstitution required | No β prefilled | No β prefilled |
The "164mg Dihydrate" Figure on 64mg Listings
Several listings for the Body Pharm Retatrutide 64mg pen carry a "164mg Retatrutide dihydrate" specification. No original Body Pharm spec sheet or pack photograph confirms this number, and it reads as a probable transcription cascade rather than a verified salt-form mass [unverified]. Procurement teams should request a high-resolution pack image or COA before treating that figure as accurate.
Picking a Format
Pick the 32mg pen if the study is a single-arm titration with a defined endpoint at week 12, or if budget approval is incremental. The 64mg pen makes more sense once the protocol extends into a maintenance phase at 8mg. The wider retatrutide research overview sets out the receptor pharmacology that justifies running protocols out to 24+ weeks at the upper dose [8].
Pen vs Vial: Format Comparison
The prefilled pen format offers fixed-step dialling and no reconstitution handling, removing one source of inter-operator variance versus lyophilised vial alternatives. Vial formats require reconstitution with bacteriostatic water and operator-defined dose volume, transferring titration accuracy risk to the researcher. The pen's sealed format also removes the post-reconstitution stability clock.
| Attribute | Body Pharm 32mg Pen | Lyophilised Vial Format |
|---|---|---|
| Reconstitution required | No | Yes (BAC water) |
| Dosing precision | Fixed-step dial (2mg steps inferred) | Operator-defined via syringe graduation |
| Cold-chain requirement | 2β8Β°C storage | 2β8Β°C reconstituted; ambient lyophilised |
| In-use stability window | Not published by manufacturer [unverified] | Depends on diluent, concentration, temperature |
| Independent COA | None located [unverified] | None located [unverified] |
| Format availability | Prefilled pen | Browse all formats |
Dosing Increments and Pen Operation for Research Use
The Body Pharm Retatrutide 32mg pen carries an 8mg upper-dose marker on the dial, with the most widely cited protocol being a 2mgβ4mgβ6mgβ8mg weekly titration. No independent laboratory has published a dose-accuracy verification or COA for the device as of May 2026 [unverified]. Researchers should treat the marker as a label-stated value, not a metrologically confirmed one.
What the Dial Actually Permits
The 2β8mg titration schedule is displayed in product documentation but does not confirm whether the mechanical selector steps in 2mg fixed increments, 1mg ticks, or finer 0.5mg graduations [unverified]. This matters for in vitro protocols requiring sub-8mg test points. If the dial is hard-coded to 2mg steps, dose-response work below 2mg or between integer values is not achievable on the pen without withdrawing into a separate syringe β which defeats the format's main advantage. Procurement teams running fractional-dose matrices should request a close-up of the selector mechanism before committing.
Why the Pen Removes One Preparation Variable
The pen ships pre-filled, removing the reconstitution step that vial formats require. Skipping bacteriostatic water volume calculation removes one source of inter-operator variance, though it transfers trust to the manufacturer's fill accuracy, which remains unverified by third parties [unverified]. The broader retatrutide research overview covers reconstitution protocols for lyophilised alternatives.
Storage Requirements and Stability Considerations
Pre-filled retatrutide pens require refrigerated storage at 2β8Β°C in their original carton to protect the peptide from light and thermal degradation, with return to room temperature recommended immediately before injection [2]. Body Pharm has not published a device-specific shelf life or post-first-use stability window for the 32mg pen as of May 2026 [unverified].
Pen Versus Vial Storage Trade-Offs
Sealed pre-filled pens remove the post-reconstitution clock that governs lyophilised vial formats. Once a vial is reconstituted with bacteriostatic water, the dissolved peptide enters a finite stability window that depends on diluent, concentration, and temperature β none of which are standardised across grey-market suppliers. The Body Pharm Retatrutide 64mg pen carries the same sealed-format advantage at higher total content but inherits the same undocumented in-use window.
Freeze-Thaw and Transit Risk
Generic peptide handling literature, summarised in the retatrutide research overview, treats freeze-thaw cycles as a known degradation vector for GLP-class peptides because ice crystal formation can rupture peptide bonds and denature the molecule. Procurement teams should specify cold-chain courier handling on receipt and reject pens that arrive frozen or warm to the touch.
Regulatory Status in South Africa: What Researchers Must Know
Retatrutide is not registered with SAHPRA for any indication as of May 2026. That places every locally available pen and vial format β including the Body Pharm Retatrutide 64mg pen and the 32mg variant β outside the registered medicines schedule. Supply, possession, and administration therefore fall under the Medicines and Related Substances Act 101 of 1965, which governs unregistered substances and Section 21 access for unapproved medicines. Products marketed as "research chemicals" sit in a legal grey zone under this framework, and enforcement posture by SAHPRA and the South African Police Service may shift without published notice. No SAHPRA circular naming retatrutide specifically had been issued in the 2024β2026 window reviewed for this guide [unverified].
International Approval and Trial Status
Retatrutide has not received marketing authorisation from the US FDA (Food and Drug Administration) or the EMA (European Medicines Agency) as of mid-2026 and remains an investigational Eli Lilly molecule [8]. May 2026 Phase 3 obesity readouts reported up to 28.3% weight loss in high-dose cohorts β newly released trial data, not evidence of approval [7]. Full regulatory submissions and peer-reviewed Phase 3 publication status as of mid-2026 should be reconfirmed before any procurement decision [unverified].
Practical Compliance Steps
Researchers reviewing the retatrutide research overview should route any acquisition through their institutional ethics committee and obtain written legal counsel on Section 21 obligations before placing orders. This guide does not endorse procurement routes that bypass SAHPRA oversight.
Procurement Diligence
Before placing an order, apply standard procurement diligence:
- Request a batch-specific certificate of analysis (COA) from support; note that no independent third-party assay data for Body Pharm pens has been publicly verified as of 2026 [unverified].
- Confirm cold-chain handling during shipping (2β8Β°C), since no manufacturer-stated in-use stability window has been published for the 32mg pen [unverified].
- Cross-check your institutional ethics documentation and Section 21 obligations under the Medicines and Related Substances Act 101 of 1965.
For protocols running beyond week 12, compare the Body Pharm Retatrutide 64mg pen on a cost-per-mg basis using the comparison table above. For parent category context, see the retatrutide research overview.
Related Research Peptides to Consider
Retatrutide rarely sits alone in a metabolic research programme. The compounds below cover adjacent mechanisms researchers typically run alongside or as comparators to the Body Pharm Retatrutide 64mg pen and the broader retatrutide research overview.
Dual and Single Incretin Comparators
Tirzepatide is a GIP/GLP-1 dual agonist and the closest mechanistic comparator to retatrutide's triple agonism, useful for isolating the contribution of glucagon receptor activity in comparative weight and glycaemic endpoints. Researchers often cross-reference the Body Pharm Tirzepatide 60mg pen against the 32mg retatrutide pen for protocol planning. Browse tirzepatide.
Semaglutide serves as the GLP-1-only baseline, allowing a three-tier comparison (GLP-1 β GIP/GLP-1 β triple agonist) within a single protocol. Browse semaglutide.
Metabolic and Tissue-Repair Adjuncts
MOTS-C, a mitochondrial-derived peptide, is used in metabolic flexibility and insulin sensitivity research, complementing incretin work on the energy expenditure side rather than appetite signalling. Browse MOTS-C.
BPC-157 sits outside the metabolic axis entirely, featuring in tissue and gastrointestinal research models where investigators want a non-incretin control compound in the same procurement cycle. Browse BPC-157.
Frequently Asked Questions
What is the difference between the 32mg and 64mg Body Pharm retatrutide pens?
The 32mg pen holds half the total peptide payload of the 64mg variant, which changes cost-per-mg economics and replacement frequency rather than per-dose strength. No primary Body Pharm spec sheet for the 64mg pen is publicly verifiable as of May 2026, and "164mg dihydrate" figures circulating on listings should be treated as unverified until manufacturer documentation is obtained [unverified]. See the Body Pharm Retatrutide 64mg pen breakdown for the side-by-side, or browse all retatrutide products.
How many doses does the 32mg pen contain at 8mg per dose?
At a maintenance dose of 8mg weekly, a 32mg pen delivers four doses if the device dispenses exactly to label, covering roughly one month of post-titration use. During the 2mgβ4mgβ6mgβ8mg ramp described in product documentation, the same pen covers a longer calendar window because earlier weeks draw smaller volumes.
Is retatrutide legal to buy in South Africa?
Retatrutide remains an investigational Eli Lilly compound with no marketing authorisation, and no SAHPRA circular naming retatrutide was located in 2024β2026 public searches [unverified][8]. It sits outside the registered medicines schedule and is handled as an unregistered investigational product, typically requiring Section 21 access for clinical use. Research procurement should be documented accordingly under the Medicines and Related Substances Act 101 of 1965.
Does the Body Pharm pen require reconstitution?
No. The Body Pharm 32mg device ships as a prefilled pen, which removes the reconstitution step required by lyophilised vial alternatives. Generic retatrutide pen guidance recommends refrigerated storage in the original container and warming to room temperature before injection, though no Body Pharm-specific in-use stability window is published [2][unverified].
Where can I buy the Body Pharm Retatrutide 32mg pen in South Africa?
The 32mg pen is listed on this page with a dedicated South African listing; the ZAR price is shown in the buy box above. You can also browse all Body Pharm retatrutide products.
What is the cost-per-mg of the Body Pharm 32mg pen?
Take the current price from the buy box above and divide by 32mg to calculate cost-per-mg. Prices fluctuate with rand volatility and stock levels, so verify at point of purchase rather than relying on cached figures.
Summary
If the 32mg pen fits your protocol window, cross-check the Body Pharm Retatrutide 64mg pen for any protocol running beyond week 12. Route any acquisition through your institutional ethics committee and obtain written legal counsel on Section 21 obligations under the Medicines and Related Substances Act 101 of 1965 before committing to purchase.
Browse all retatrutide products | Browse all peptides
For research use only. Not for human consumption.
